Koch, Elias A. T.
Petzold, Anne
Wessely, Anja
Dippel, Edgar
Erdmann, Michael
Heinzerling, Lucie
Hohberger, Bettina
Knorr, Harald
Leiter, Ulrike
Meier, Friedegund
Mohr, Peter
Rahimi, Farnaz
Schell, Beatrice
Schlaak, Max
Terheyden, Patrick
Schuler-Thurner, Beatrice
Ugurel, Selma
Utikal, Jochen
Vera, Julio
Weichenthal, Michael
Ziller, Fabian
Berking, Carola
Heppt, Markus V. http://orcid.org/0000-0003-4603-1825
Funding for this research was provided by:
Universitätsklinikum Erlangen
Article History
Received: 2 June 2021
Accepted: 12 October 2021
First Online: 28 October 2021
Declarations
:
: Carola Berking reports personal fees and non-financial support from BMS, personal fees from MSD, personal fees from Novartis, personal fees from Leo Pharma, personal fees from Regeneron, personal fees from Immunocore, personal fees from Sanofi-Genzyme, personal fees from Sanofi-Aventis, personal fees from Almirall-Hermal, personal fees from Roche, personal fees from Pierre Fabre, from Merck, outside the submitted work. Lucie Heinzerling declares research support from Novartis; speakers and advisory board honoraria from Bristol Myers Squibb, CureVac, Merck Sharp & Dohme, Novartis, Pierre Fabre, Sanofi, and Roche. Beatrice Schell reports receiving speaker’s honoraria and/or travel support from Amgen, BMS, MSD, Janssen, Novartis, Roche, Sun Pharma, Abbvie, and Pfizer. Max Schlaak reports receiving honoraria and participation in advisory boards of Bristol Myers Squibb, Novartis, MSD, Roche, Pierre Fabre, Kyowa Kirin, Immunocore, and Sanofi-Genzyme. Max Schlaak received travel accommodation and expenses from Novartis, Pierre Fabre, and Sun Pharma. Patrick Terheyden received speaker’s honoraria from BMS, Novartis, MSD, Pierre Fabre, CureVac, and Roche, consultant´s honoraria from BMS, Novartis, Pierre Fabre, Merck Serono, Sanofi und Roche and travel support from BMS, Pierre Fabre and Roche. Selma Ugurel declares research support from Bristol Myers Squibb and Merck Serono; speakers and advisory board honoraria from Bristol Myers Squibb, Merck Sharp & Dohme, Merck Serono, Novartis and Roche, and travel support from Bristol Myers Squibb, and Merck Sharp & Dohme. Jochen Utikal is on the advisory board or has received honoraria and travel support from Amgen, Bristol Myers Squibb, GSK, LeoPharma, Merck Sharp and Dohme, Novartis, Pierre Fabre, Roche, Sanofi outside the submitted work. Michael Weichenthal reports grants and personal fees from Merck, grants and personal fees from Bristol Myers Squibb, grants and personal fees from Novartis, grants and personal fees from Millennium, personal fees from Kyowa Kirin, personal fees from Takeda, personal fees from Medac, personal fees from Sun Pharma, personal fees from Pierre Fabre, personal fees from Roche, personal fees from Sanofi, outside the submitted work. Fabian Ziller reports personal fees from Bristol Myers Squibb GmbH & Co KG, Munich, personal fees from MSD SHARP & DOHME GmbH, Haar, personal fees from Roche Pharma AG, Grenzach-Wyhlen, personal fees from GlaxoSmithKline GmbH & Co KG, Munich, personal fees from Sanofi-Aventis GmbH, Berlin, personal fees from Novartis Pharma GmbH, Nürnberg, outside the submitted work. All other authors declare no conflict of interest.
: This study was approved by the scientific board of the registry and by the institutional review board of the medical faculty of the Munich University Hospital (Approval Number 413–16 UE) and conducted following the principles of the Helsinki Declaration in its current version.